Active, not recruitingNCT05228158
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eisai Co., Ltd.
- Intervention
- Tazemetostat(drug)
- Enrollment
- 145 target
- Eligibility
- All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- Eisai Trial Site 131, Komaki-shi, Aichi-ken, Japan
- Eisai Trial Site 199, Konan-shi, Aichi-ken, Japan
- Eisai Trial Site 21, Nagakute-shi, Aichi-ken, Japan
- Eisai Trial Site 106, Nagoya, Aichi-ken, Japan
- Eisai Trial Site 156, Nagoya, Aichi-ken, Japan
- Eisai Trial Site 174, Nagoya, Aichi-ken, Japan
- Eisai Trial Site 91, Nagoya, Aichi-ken, Japan
- Eisai Trial Site 170, Okazaki-shi, Aichi-ken, Japan
- Eisai Trial Site 181, Seto-shi, Aichi-ken, Japan
- Eisai Trial Site 130, Toyohashi, Aichi-ken, Japan
- Eisai Trial Site 226, Toyokawa-shi, Aichi-ken, Japan
- Eisai Trial Site 133, Toyota-shi, Aichi-ken, Japan
- Eisai Trial Site 205, Yatomi-shi, Aichi-ken, Japan
- Eisai Trial Site 240, Akita, Akita, Japan
- Eisai Trial Site 234, Hirosaki-shi, Aomori, Japan
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05228158 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca